Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?

Core Viewpoint - Acadia Pharmaceuticals has experienced a decline in share price by approximately 12.9% since its last earnings report, underperforming the S&P 500, raising questions about its future performance leading up to the next earnings release [1]. Financial Performance - In Q4 2025, Acadia reported earnings per share (EPS) of 16 cents, exceeding the Zacks Consensus Estimate of 12 cents, but down from 17 cents in the same quarter the previous year [2]. - Total revenues for Q4 2025 were $284 million, falling short of the Zacks Consensus Estimate of $293 million, but reflecting a 9% year-over-year increase driven by Daybue and Nuplazid [3]. - Nuplazid revenues increased by 7% year-over-year to $174.4 million, although it missed the consensus estimate of $184.1 million [4]. - Daybue achieved net product sales of $109.6 million in Q4 2025, a 13% year-over-year increase, slightly surpassing the consensus estimate of $108.4 million [4]. - For the full year 2025, Acadia's total revenues reached $1.07 billion, a 12% increase year-over-year, but below the consensus estimate of $1.08 billion [7]. Expenses and Cash Position - Research and development (R&D) expenses were $84.8 million, down 16% year-over-year, while selling, general and administrative (SG&A) expenses rose by 20% to $155.6 million due to increased marketing investments [5]. - As of December 31, 2025, Acadia had cash, cash equivalents, and investments totaling $820 million, a decrease from $847 million as of September 30, 2025 [6]. Future Outlook - For 2026, Acadia anticipates total revenues from U.S. sales to be between $1.22 billion and $1.28 billion, with Nuplazid sales projected at $760 million to $790 million and Daybue sales expected to be between $460 million and $490 million [8]. - R&D expenses for 2026 are projected to be between $385 million and $410 million, while SG&A expenses are expected to range from $660 million to $700 million [8]. Market Sentiment - Recent estimates for Acadia have trended downward, with a significant shift of -60.94% in consensus estimates over the past month [9]. - Acadia currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [11]. - The company has a subpar Growth Score of D and a Momentum Score of F, with an aggregate VGM Score of F, suggesting challenges in multiple investment strategies [10].